MORRISVILLE, N.C. — Trimeris, the maker of the anti-AIDS drug Fuzeon, is shaking up its management team, cutting workers and reducing programs in an attempt to improve profitability.

Trimeris (Nasdaq: TRMS) announced just as the markets closed on Tuesday that Chief Executive Officer Steven Skolsky was leaving “to pursue other opportunities.”

At the same time, Dani Bolognesi, the CEO Skolsky replaced, will return as CEO. He also will keep his title as chief scientific officer, Trimeris said in a statement.

Trimeris also will cut workers and programs.

The company said it would improve earnings “by sharply reducing expenses.”

Trimeris is en route to profitability for the first time as a company this year, based on increasing global sales for Fuzeon. Trimeris partners with drug giant Roche to produce, market and sell the drug.